JFJoud Fahed

Joud Fahed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Joud Fahed has a total of 33 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Outcomes of cardiac myosin inhibitors in hypertrophic cardiomyopathy: an updated brief meta-analysis

    by Joud Fahed, Asad Ur Rab, Mohammad Hamza, Rehman Afraz, Ali Awad, Abdul Monem Al Riahi, Prakash Upreti

    Obstructive hypertrophic cardiomyopathy (HCM) is a common inherited cardiac disease occurring in approximately 1 in 500 adults worldwide, characterized by left ventricular outflow tract (LVOT) obstruction, symptoms of heart failure, and increased risk of sudden cardiac death.

  • In-hospital outcomes of catheter-directed therapies for pulmonary embolism in the United States 2016–2022

    by Mohammad Ali Sheffeh, Andrew Gregory, John Gallagher, Joshua Moyal, Judy Sheffeh, Diana Kailouh, Ider Oujamaa, Joud Fahed, Peter A. Soukas, M Chadi Alraies, et al.

  • Durability of sotatercept response in pulmonary hypertension: Insights from extended real-world follow-up

    by Azka Naeem, Olayiwola Bolaji, George G. Kidess, Joud Fahed, Sultana Jahan, Jawad Basit, Muhammad Hashim Khan, Shaunak Mangeshkar, Steven Sorci, Hayah Kassis-George, et al.


  • Open Access

    Long-Term Clinical Outcomes of Sotatercept in Pulmonary Hypertension: A Retrospective Cohort Analysis

    by Azka Naeem, Olayiwola Bolaji, George G. Kidess, Joud Fahed, Sultana Jahan, Muhammad Hashim Khan, Shaunak Mangeshkar, Steven Sorci, Hayah Kassis-George, Sourbha Dani, et al.

    Background: Sotatercept, an activin receptor ligand trap, has demonstrated significant short-term hemodynamic improvements in pulmonary hypertension (PH) based on clinical trials. However, evidence regarding long-term outcomes in real-world settings remains limited. Methods: Using data from the TriNetX global federated health research network covering 102 healthcare organizations, we conducted a retrospective cohort study comparing 185 patients with PH receiving sotatercept to 212,349 PH patients not receiving sotatercept. After 1:1 propensity score matching to balance baseline characteristics, we assessed outcomes at 6 months, 1 year, 3 years, and 5 years post-initiation and cox proportional hazards was used. Primary outcomes included all-cause mortality, rehospitalization rates, major adverse cardiovascular events (MACE), and BNP elevation (≥100 pg/mL). Results: Over 5 years of follow-up, sotatercept treatment was associated with significantly lower all-cause mortality (5.4% vs. 27.3%; risk difference, -21.9 percentage points [95% CI, -29.1 to -14.7]; p<0.001; hazard ratio [HR], 0.40 [95% CI, 0.16-0.99]). Rehospitalization rates were also substantially reduced in the sotatercept group (15.4% vs. 38.1%; risk difference, -22.8 percentage points [95% CI, - 35.8 to -9.7]; p=0.002; HR, 0.12 [95% CI, 0.03-0.49]). MACE occurrence was significantly lower with sotatercept (6.4% vs. 15.5%; risk difference, -9.1 percentage points [95% CI, -16.2 to -2.0]; p=0.011; HR, 0.45 [95% CI, 0.14-1.41]), while BNP elevation showed no significant difference (12.8% vs. 10.6%; p=0.626). Treatment benefits were observed as early as 6 months post-initiation, progressively increasing magnitude through 5 years of follow-up. Sensitivity analyses using alternative matching methods and instrumental variable approaches confirmed the robustness of these findings. Conclusions: In this large real-world cohort study with long-term follow-up, sotatercept was associated with substantial reductions in mortality, rehospitalization, and cardiovascular events in patients with pulmonary hypertension. These benefits increased over time, suggesting potential disease-modifying effects beyond acute hemodynamic improvements. These findings complement data from randomized controlled trials and support the role of sotatercept in improving long-term outcomes in pulmonary hypertension.

  • Open Access

    Transcatheter Aortic Valve Replacement (TAVR)-Induced Hemodynamically Unstable Supraventricular Tachycardia in an Elderly Patient With a Complex Cardiovascular History

    by Joud Fahed, Abdul Mohammad, Rehman Afraz, Danhue Moodie, Claudia Georges

    Transcatheter aortic valve replacement (TAVR) is an important alternative to surgical aortic valve replacement (SAVR) as it reduces stay length and complication rates. Despite this apparent advantage, clinicians must still be aware of these complications. In this paper, we present a case of an elderly female who had an ICD placed years before presentation, presenting with wide complex tachycardia weeks after the TAVR procedure. In this case, the differentiation between ventricular tachycardia and supraventricular tachycardia with aberrancy proved to be a diagnostic challenge. This case highlights an arrhythmia-related complication stemming from TAVR and the utility of the Implantable cardioverter defibrillator (ICD) as an important diagnostic tool in differentiating these rhythms and confirming the temporal relationship between this arrhythmia and the valve replacement procedure.

  • Open Access

    A potential protective role of congenital peritoneal encapsulation coexisting with metastatic colon cancer: a rare case report

    by Youssef Ahmad, Joud Fahed, Jebrail Mousa, Fadi Souleiman

    Introduction and importance: Congenital peritoneal encapsulation (CPE) is a rare condition in which the small intestine is encased within a mesothelial-lined sac. The following case is an extremely rare description of the co-existence of both colon cancer and peritoneal encapsulation, highlighting the potential role of this co-existence in preventing the spread of metastases and tumor implantation. Case-presentation: A 60-year-old female was diagnosed with metastatic colon cancer. During the operation, a thin fibrous membrane was found covering the small intestine, which suggested CPE. The tumor was removed, and the additional membrane was totally excised. The patient is currently receiving chemotherapy for metastatic treatment and is in good health. Clinical discussion: CPE is a medical condition that results from abnormal peritoneal development, and it is often confused with other differential diagnoses resulting from inflammatory causes. It can occur at different ages and remains asymptomatic for the majority of cases. However, it can be a potential cause of bowel obstruction. An intraoperative diagnosis can easily differentiate the case. The co-existence with colon cancer has been described only once in the literature. Conclusion: Peritoneal encapsulation is a rare, mostly asymptomatic condition. However, it may play a protective role in preventing metastatic colon cancer from affecting the small intestine, thus potentially opening up new avenues for the treatment of cancer metastases.